Abstract
This review will focus on the construction, refinement, and validation of G Protein-coupled receptor models for the purpose of structure-based virtual screening. Practical tips and tricks derived from concrete modeling and virtual screening exercises to overcome the problems and pitfalls associated with the different steps of the receptor modeling workflow will be presented. These examples will not only include rhodopsin-like (class A), but also secretine-like (class B), and glutamate-like (class C) receptors. In addition, the review will present a careful comparative analysis of current crystal structures and their implication on homology modeling. The following themes will be discussed: i) the use of experimental anchors in guiding the modeling procedure; ii) amino acid sequence alignments; iii) ligand binding mode accommodation and binding cavity expansion; iv) proline-induced kinks in transmembrane helices; v) binding mode prediction and virtual screening by receptor-ligand interaction fingerprint scoring; vi) extracellular loop modeling; vii) virtual filtering schemes. Finally, an overview of several successful structure-based screening shows that receptor models, despite structural inaccuracies, can be efficiently used to find novel ligands.
Keywords: GPCR, modeling, virtual screening, drug design
Current Pharmaceutical Design
Title: Customizing G Protein-Coupled Receptor Models for Structure-Based Virtual Screening
Volume: 15 Issue: 35
Author(s): Chris de Graaf and Didier Rognan
Affiliation:
Keywords: GPCR, modeling, virtual screening, drug design
Abstract: This review will focus on the construction, refinement, and validation of G Protein-coupled receptor models for the purpose of structure-based virtual screening. Practical tips and tricks derived from concrete modeling and virtual screening exercises to overcome the problems and pitfalls associated with the different steps of the receptor modeling workflow will be presented. These examples will not only include rhodopsin-like (class A), but also secretine-like (class B), and glutamate-like (class C) receptors. In addition, the review will present a careful comparative analysis of current crystal structures and their implication on homology modeling. The following themes will be discussed: i) the use of experimental anchors in guiding the modeling procedure; ii) amino acid sequence alignments; iii) ligand binding mode accommodation and binding cavity expansion; iv) proline-induced kinks in transmembrane helices; v) binding mode prediction and virtual screening by receptor-ligand interaction fingerprint scoring; vi) extracellular loop modeling; vii) virtual filtering schemes. Finally, an overview of several successful structure-based screening shows that receptor models, despite structural inaccuracies, can be efficiently used to find novel ligands.
Export Options
About this article
Cite this article as:
de Graaf Chris and Rognan Didier, Customizing G Protein-Coupled Receptor Models for Structure-Based Virtual Screening, Current Pharmaceutical Design 2009; 15 (35) . https://dx.doi.org/10.2174/138161209789824786
DOI https://dx.doi.org/10.2174/138161209789824786 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Congenital Cytomegalovirus Infection: Virus-Host Interaction for Defense and Transmission
Current Pharmaceutical Biotechnology Incidence and Management of Carfilzomib-induced Cardiovascular Toxicity; A Systematic Review and Meta-analysis
Cardiovascular & Hematological Disorders-Drug Targets The Roles of Parathyroid Hormone and Calcitonin in Bone Remodeling: Prospects for Novel Therapeutics
Endocrine, Metabolic & Immune Disorders - Drug Targets ISCHEMIRs: Finding a Way Through the Obstructed Cerebral Arteries
Current Drug Targets HM74a Agonists: Will they be the New Generation of Nicotinic Acid?
Current Topics in Medicinal Chemistry Reappraisal of Antimalarials in Interferonopathies: New Perspectives for Old Drugs
Current Medicinal Chemistry Etoposide, Topoisomerase II and Cancer
Current Medicinal Chemistry - Anti-Cancer Agents Diabetes Mellitus: Channeling Care through Cellular Discovery
Current Neurovascular Research Hypercoagulability and Nephrotic Syndrome
Current Vascular Pharmacology Patent Annotations
Recent Patents on Anti-Infective Drug Discovery Preface [Hot Topic: Transcription Factors as Targets of Novel Therapeutic Approaches of Autoimmune Diseases (Executive Editor: Gunther Ne)]
Current Pharmaceutical Design Hepatitis C Virus NS3/4A Protease Inhibitors
Recent Patents on Anti-Infective Drug Discovery Prophylactic and Therapeutic Approaches Against Respiratory Syncytial Virus
Current Medicinal Chemistry - Anti-Infective Agents Natural Rubber Latex Allergy in Pediatric Patients
Current Pediatric Reviews Present, Emerging and Possible Future Biomarkers in Castration Resistant Prostate Cancer (CRPC)
Current Cancer Drug Targets The Use of Naltrexone in Dermatology. Current Evidence and Future Directions
Current Drug Targets Liver Injury Associated with Antidepressants
Current Drug Safety Tetracyclines: Drugs with Huge Therapeutic Potential
Mini-Reviews in Medicinal Chemistry Development of an Insect Cell-Free System
Current Pharmaceutical Biotechnology Ion Channel Defects in Idiopathic Epilepsies
Current Pharmaceutical Design